

ERRATUM

In the article by Ford et al,¹ the Conflict of Interest statement was mistakenly omitted from the published version of the article. This error was the result of an oversight by the typesetter. The statement follows.

Conflict of Interest Statement:

Tobias Kurth reports having contributed to an advisory board of CoLucid and a research project funded by Amgen, for which the Charité – Universitätsmedizin Berlin received an unrestricted compensation. He further reports having received honoraria from Eli Lilly and Company, Newsenselab, and Total for providing methodological advice, from Novartis and from Daiichi Sankyo for providing a lecture on neuroepidemiology and research methods, and from the BMJ for editorial services. Amaal Starling reports consulting fees from Alder, Amgen, Eli Lilly and Company, eNeura, Impel, Lundbeck, Novartis, and Theranica; honoraria from Medscape, Migraine World Summit, and Research America; and research funding from Migraine Research Foundation and Mayo Clinic. All other authors are employees and minor stockholders of Eli Lilly and Company or Lilly USA, LLC.

The Publisher apologizes for this error.

REFERENCE

1. Ford JH, Kurth T, Starling AJ, et al. Migraine headache day response rates and the implications to patient functioning: An evaluation of 3 randomized phase 3 clinical trials of galcanezumab in patients with migraine. *Headache*. 2020;60:2304-2319.